VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
February 10, 2022 16:20 ET
|
VistaGen Therapeutics, Inc.
Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to evaluate PH94B in social anxiety disorder (SAD)...
Central Nervous System Therapeutic Market Size to Hit US$ 209.2 Bn by 2030
February 08, 2022 10:00 ET
|
Precedence Research
Ottawa, Feb. 08, 2022 (GLOBE NEWSWIRE) -- The global central nervous system therapeutics market size was valued at US$ 113.6 billion in 2020. The rising prevalence of various central nervous system...
Vyant Bio to Present at the H.C. Wainwright Bioconnect Conference
January 10, 2022 08:00 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Central Nervous System Treatment Market Size [2022-2028] | is Anticipated to Reach USD 166.53 Billion, Exhibit a CAGR 0f 9.4%
January 07, 2022 03:53 ET
|
Fortune Business Insights
Pune, India, Jan. 07, 2022 (GLOBE NEWSWIRE) -- The global central nervous system treatment market size is anticipated to reach USD 166.53 billion by 2028 and exhibit a CAGR 0f 9.4% during the...
VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference
November 16, 2021 08:30 ET
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of...
Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference
November 10, 2021 16:15 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
October 14, 2021 08:00 ET
|
VistaGen Therapeutics, Inc.
Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional Anxiety Disorders Phase 2A Study in Adjustment Disorder to Run in Parallel with Ongoing Phase 3...
Vyant Bio to Present at the H.C. Wainwright 23rd Annual Global Conference
September 09, 2021 08:00 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 16, 2021 08:00 ET
|
Praxis Precision Medicines, Inc.
Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...
Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms
August 16, 2021 07:55 ET
|
Praxis Precision Medicines, Inc.
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile ...